Aptose biosciences inc. (APTO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from/(used in) operating activities:
Net loss for the period

-26,277

-28,868

-11,643

-

-

Items not involving cash:
Stock-based compensation

2,296

4,276

817

-

-

Shares issued to Aspire Capital as commitment fees

360

600

-

-

-

Depreciation and amortization

152

87

84

-

-

Amortization of right-of-use assets

461

-

-

-

-

Interest on lease liabilities

90

-

-

-

-

Unrealized foreign exchange (gain)/loss

23

-25

25

-

-

Accrued interest on investments

34

-

-

-

-

Change in operating working capital:
Prepaid expenses

379

324

-70

-

-

Other assets

40

27

-27

-

-

Operating lease payments

471

-

-

-

-

Accounts payable

645

726

589

-

-

Accrued liabilities

1,662

298

-142

-

-

Cash used in operating activities

-21,558

-23,207

-10,223

-

-

Cash flows from financing activities:
Offering costs paid

437

15

0

-

-

Issuance of common shares under exercise of stock options

718

240

-

-

-

Cash provided by financing activities

103,448

27,871

13,718

-

-

Cash flows from/(used in) investing activities:
Acquisition of investments, net

17,268

-341

798

-

-

Purchase of property and equipment

102

329

13

-

-

Cash used in investing activities

-17,370

12

-811

-

-

Effect of exchange rate fluctuations on cash and cash equivalents held

23

-8

7

-

-

Increase (decrease) in cash and cash equivalents

64,543

4,668

2,691

-

-

Net loss for the period

-

-

-

-14,240

-11,711

Stock-based compensation

-

-

-

1,706

2,500

Depreciation and amortization

-

-

-

116

75

Interest income

-

-

-

79

226

Unrealized foreign exchange (loss) gain

-

-

-

233

-726

Interest and accretion expense

-

-

-

0

34

Change in non-cash operating working capital (note 8)

-

-

-

126

-163

Cash used in operating activities

-

-

-

-12,390

-9,891

Issuance of common shares under the ATM, net of issuance costs (note 9(b)(ii))

-

-

-

5,726

8

Issuance of common shares under Share Purchase Agreement (note 6(a)(ii))

-

-

-

0

0

Exercise of warrants, options and DSUs (note 9)

-

-

-

0

798

Interest paid on notes and loans

-

-

-

0

21

Cash provided by financing activities

-

-

-

5,726

785

Maturity (acquisition) of investments

-

-

-

6,401

6,205

Purchase of property and equipment

-

-

-

3

258

Interest received

-

-

-

79

226

Cash provided by (used in) investing activities

-

-

-

6,477

6,173

Effect of exchange rate fluctuations on cash and cash equivalents held

-

-

-

-184

-1,139

Increase (decrease) in cash and cash equivalents

-

-

-

-371

-4,072

ATM Offering [Member]
Issuance of common shares

-

-

13,525

-

-

The 2017 Purchase Agreement [Member]
Issuance of common shares

-

-

500

-

-

Issuance of common shares

-

15,000

-

-

-

The 2019 Share Purchase Agreement [Member]
Issuance of common shares

4,370

-

-

-

-

December 2019 Public Offering [Member]
Issuance of common shares

68,883

-

-

-

-

June 2019 Public Offering [Member]
Issuance of common shares

19,736

-

-

-

-

The 2018 ATM Offering [Member]
Issuance of common shares

178

10,720

-

-

-

The 2018 Purchase Agreement [Member]
Issuance of common shares

10,000

1,926

-

-

-